Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy

It has recently become clear that interferon-beta (IFN-beta) treatment is effective in ameliorating relapsing-remitting multiple sclerosis (RRMS) through an as yet unidentified mechanism. As there is no recognisable biological indicator to predict responsiveness to IFN-beta treatment, we have invest...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2004-03, Vol.148 (1-2), p.206-211
Main Authors: Fainardi, Enrico, Rizzo, Roberta, Melchiorri, Loredana, Castellazzi, Massimiliano, Govoni, Vittorio, Caniatti, Luisa, Paolino, Ezio, Tola, Maria Rosaria, Granieri, Enrico, Baricordi, Olavio Roberto
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Disability Evaluation
Enzyme-Linked Immunosorbent Assay - methods
Female
HLA Antigens - blood
Humans
Interferon beta-1b
Interferon-beta - therapeutic use
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting - blood
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Statistics, Nonparametric
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has recently become clear that interferon-beta (IFN-beta) treatment is effective in ameliorating relapsing-remitting multiple sclerosis (RRMS) through an as yet unidentified mechanism. As there is no recognisable biological indicator to predict responsiveness to IFN-beta treatment, we have investigated fluctuations in serum sHLA-I levels in MS patients undergoing IFN-beta 1b therapy. Serum sHLA-I concentrations measured by enzyme-linked immunosorbent assay (ELISA) were assessed at baseline and, longitudinally, over a period of 18 months after the start of treatment in 29 RRMS patients grouped as responders and nonresponders according to their clinical response to IFN-beta 1b therapy. Thirty-nine healthy volunteers served as controls. Serum sHLA-I concentrations were significantly higher (p
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2003.12.002